Welcome to Predictive Oncology
The leading edge of a new frontier in drug discovery
Integrating scientific rigor with machine learning • Overcoming challenges of clinical trials • Improving the probability of success • Collaborating with partners in biopharma • Advancing molecules to medicine with confidence and accuracy
Drug discovery
Bring the human element into pre-clinical discovery. Our proprietary platform pairs AI with the richness of data derived from the world's largest privately held biobank of tumor samples to make drug-response predictions within a heterogeneous collection. Our 3D tumor models mimic the complex human organ microenvironment for high correlation with clinical response.
Clinical testing
Personalize cancer therapies more effectively. Our advanced tumor drug-response testing and genomic profiling services help to individualize treatment plans for better patient outcomes.
Introduce the human element earlier with our integrated AI/ML solution.
Don’t wait until clinical trials. Our powerful predictive engine is made possible by the tumor features contained in our highly diversified biobank of over 150K tumor samples. This increases the likelihood of drug efficacy by efficiently addressing tumor heterogeneity.
Our AI solution can make high-confidence predictions of drug response enabling a more informed selection of drug/tumor type combinations to increase the probability of success during development.
Optimize drug discovery
with 3D models.
Leverage complex in vitro models that better mimic the physiological environment of human tissue to provide a more clinically relevant testing platform than commonly used alternatives.
Let’s discover and develop together.
We want to hear about your process challenges—and identify ways to solve them together. Complete the form to get in touch with our team of experts.
News & resources
Heterogeneous and curated biobank of live-cell tumor samples retains highly reproducible drug response data for drug and biomarker discovery
White paper validates highly reproducible drug response data. Results enable AI platform to model and predict patient outcomes on historical samples Leveraging more than 20...Learn more
Increasing the probability of technical success in drug development using AI and patient heterogeneity.
A recent white paper released by Predictive Oncology’s highlights the challenge of late-stage clinical trial failures and the company’s ability to better navigate those obstacles...Learn more
Predictive Oncology enters biomarker discovery market after successful retrospective ovarian cancer study yields compelling results
Company expands AI/ML driven capabilities to pursue novel biomarker discovery to predict patient outcomes and drug response in oncology. Read our white paper below that...Learn more
Heterogeneous and curated biobank of live-cell tumor samples retains highly reproducible drug response data for drug and biomarker discovery
White paper validates highly reproducible drug response data. Results enable AI platform to model and predict patient outcomes on historical samples Leveraging more than 20...Learn more
Increasing the probability of technical success in drug development using AI and patient heterogeneity.
A recent white paper released by Predictive Oncology’s highlights the challenge of late-stage clinical trial failures and the company’s ability to better navigate those obstacles...Learn more
Predictive Oncology enters biomarker discovery market after successful retrospective ovarian cancer study yields compelling results
Company expands AI/ML driven capabilities to pursue novel biomarker discovery to predict patient outcomes and drug response in oncology. Read our white paper below that...Learn more
Heterogeneous and curated biobank of live-cell tumor samples retains highly reproducible drug response data for drug and biomarker discovery
White paper validates highly reproducible drug response data. Results enable AI platform to model and predict patient outcomes on historical samples Leveraging more than 20...Learn more
Increasing the probability of technical success in drug development using AI and patient heterogeneity.
A recent white paper released by Predictive Oncology’s highlights the challenge of late-stage clinical trial failures and the company’s ability to better navigate those obstacles...Learn more
Predictive Oncology enters biomarker discovery market after successful retrospective ovarian cancer study yields compelling results
Company expands AI/ML driven capabilities to pursue novel biomarker discovery to predict patient outcomes and drug response in oncology. Read our white paper below that...Learn more
